Thema: Studie: Thalidomide Analog, CC-5013

A Phase I Trial of a Thalidomide Analog, CC-5013, for the Treatment of patients with Recurrent High-Grade Gliomas

Phase: Phase 1

Age Group: Adults Only

Min Karnofsky Score: 60
Requires occasional assistance but is able to care for most of own needs

Conditions:

Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients with recurrent or progressive high-grade gliomas or patients with a clinical and radiographic diagnosis of brainstem glioma. Patients must have failed prior radiation therapy. Greater than or equal to 18 years old. Recovered from chemotherapy effects. Patients must be on a stable dose of steroids five days prior to registration.

Tumor Types:
Anaplastic Astrocytoma
Brainstem Glioma
Ependyoma
Glioblastoma Multiforme
Gliosarcoma
Hemangioblastoma
Meningioma
Mixed Glioma
Oligodendroglioma High Grade
PNET Tumor


Comments:
CC-5013 is an oral agent taken daily for 3 weeks with 1 week rest. MRI/CT of brain every 4 weeks. Dose escalating, toxicity trial.


Contact:

Howard Fine MD
Branch, Chief
National Cancer Institute and National Institute of neurologic Disorder and Stroke
Bloch Bldg 82, MSC 8200
9030 Old Georgetown Road
Bethesda, MD 20892-8200 USA
Phone: 301-402-6298
Fax: (301)480-2246